New Drug: Infigratinib for FGFR2+ cholangiocarcinoma
|New Drug: Infigratinib for FGFR2+ cholangiocarcinoma|
J Clin Oncol 2021;39(3):suppl 265-265
Javle MM, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangementhttps://doi.org/10.1200/JCO.2021.39.3_suppl.265
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.